Acuity enhancement

From PsychonautWiki
(Redirected from Visual acuity enhancement)
Jump to navigation Jump to search
Visual acuity enhancement by StingrayZ - This animation serves as a replication of visual acuity enhancement, which is a common psychedelic effect. It demonstrates the general differences between normal vision and acuity enhancement by shifting between the two states. There is also a subtle amount of visual drifting within this replication.

Acuity enhancement is defined as a heightening of the clearness and clarity of vision. This results in the visual details of the external environment becoming sharpened to the point where the edges of objects become perceived as extremely focused, clear, and defined. The experience of acuity enhancement can be likened to bringing a camera or projector lens that was slightly blurry into focus. At its highest level, a person may experience the ability to observe and comprehend their entire visual field simultaneously, including their peripheral vision. This is in contrast to the default sober state where a person is only able to perceive the small area of central vision in detail.[1]

While under the influence of this effect, it is common for people to suddenly notice patterns and details in the environment they may have never previously noticed or appreciated. For example, the complexity and perceived beauty of the visual input often become apparent when looking at sceneries, nature, and everyday textures.

Acuity enhancement is often accompanied by other coinciding effects such as color enhancement and pattern recognition enhancement.[2][3] It is most commonly induced under the influence of mild dosages of psychedelic compounds, such as LSD, psilocybin, and mescaline. However, it can also occur to a lesser extent under the influence of certain stimulants and dissociatives such as MDMA or 3-MeO-PCP.

Image examples

 Caption
Tree Bark.jpgTree Bark by Chelsea Morgan
5-MAPB
3-MeO-PCE
4-AcO-DiPT
2C-D
Aniracetam
LSM-775
LSD
2C-B-FLY
Experience:337mg DMT fumarate - A Day With DMT
Βk-2C-B
PARGY-LAD
Psilocybin mushrooms
Experience:800 seeds LSA - My First Trip Ever
Phenylpiracetam
Pramiracetam
25C-NBOMe
25D-NBOMe
5-MeO-MiPT
Bufotenin
4-AcO-MiPT
4-HO-MPT
Experience: 36mg 4-AcO-DiPT - Truly, one for the psychedelic animals among us
2C-P
5-MeO-DiBF
Experience:BK-2C-B - Various experiences
Amanita muscaria
Experience:20mg - I looked up and saw an angry god-like figure made of clouds glaring down at me
Omberacetam
Experience:4.5g - The Grand Introduction to Beauty and Fear
Lisdexamfetamine
4-AcO-DET
Moss on tree bark.jpgMoss on tree Bark by Chelsea Morgan
2C-T-2
2C-E
TMA-2
MDA
Methallylescaline
4-HO-DiPT
Experience:40mg - Brothermind and the Forest's Hand
25B-NBOMe
ETH-LAD
Experience:26mg - Stage 3 Trip
3C-E
Experience:4x 200ug tabs - You do not need to understand
25I-NBOMe
ALD-52
Experience:3.5g psilocybe cubensis - Relinquishing of Material Chains/Fear and Desolation
TMA-6
Phenethylamine (compound)
Experience:3 Grams of Mushrooms - Reset on my Life, Experiencing Satori and the Cosmic Perspective
4-HO-DPT
MPT
4-HO-EPT
Mescaline
DMT
4-AcO-DMT
1P-LSD
Experience:LSA (20 HWBR seeds) – A pleasant adventure with a harsh body load
2C-I
LSA
Efavirenz
4-HO-MiPT
DET
Ayahuasca
Experience: 15mg 2C-B (oral) - A pleasant low-dose evening with Nexus
Experience: 5-EAPB (60mg) + 2-FMA (20mg) + 4-AcO-DMT (10mg) - Emotional catharsis
1B-LSD
LSZ
Experience:150mg MDMA + 20mg 2C-B - I designed it this way myself
4-HO-DET
1P-ETH-LAD
Experience:2mg 25C-NBOMe - Experimental trip to test personal limits of NBOMes
Oxiracetam
Allylescaline
Experience:3 drops of cinnamon bark oil/ 5 drops of german chamomile oil/ 2mL of nutmeg oil in lecithin - experiments with nutmeg oil
Experience: 1.5g Psilocybe Cubensis - Analysis of body and mind
AL-LAD
Proscaline
Memantine
Experience:LSD (120ug) - An Overdose of LSD and Trip into Insanity
Experience:3g mimosa / 3g syrian rue - Connecting with my body
MiPLA
PRO-LAD
Selective serotonin reuptake inhibitor
5-MeO-DMT
25B-NBOH
25C-NBOH
5-MeO-DiPT
Experience:300µg LSD - Togetherness and the Silent Dusk
Piracetam
2C-T-21
Coluracetam
25I-NBOH
DOB
4-HO-MET
2-Aminoindane
Psilocin
MET
Experience:5.3g psilocybe cubensis - Dimensional Circumstance and the Fabric of Understanding
3-MeO-PCP
MiPT
Desoxypipradrol
DOC
Bromo-DragonFLY
Citicoline
MDAI
Towel.jpgTowel by Chelsea Morgan
2C-B
Experience:25mg 3-MeO-PCP - Enhanced film experience
Experience:Mushrooms and Snuff Films -- Trip Report (3.5 grams)
4-AcO-MET
5-MeO-DALT
Escaline
DOI
Experience:60mg 4-AcO-DMT Nonstop Quasi-Orgasmic Objectless Euphoria
2C-C
2C-T-7
Experience:2.5g Mushrooms + 500mg DMT
DOM
3,4-CTMP
Ibogaine
25N-NBOMe
ΑMT
DPT

Analysis

It is thought that a fundamental feature of information-processing dysfunction in both hallucinogen-induced states and schizophrenia-spectrum disorders is the inability of these people to screen out, inhibit, filter, or gate irrelevant stimuli and to attend selectively to more important features of the environment.[4][5][6]

The CSTC model of the brain posits that the thalamus plays a key role in controlling or gating external sensory information to the conscious faculties and is thereby fundamentally involved in the regulation of a person's awareness and attention.[7][8][9][10] The interruption of psychedelics to these neural pathways that inhibit the sensory gating systems[11][10] may, therefore, result in an enhanced availability of sensory information which is usually filtered out by these systems. This process is likely also involved in the various visual, tactile, and auditory enhancements which commonly occur when under the influence of a psychedelic experience.

Psychoactive substances

Compounds within our psychoactive substance index which may cause this effect include:

... further results

Experience reports

Anecdotal reports which describe this effect within our experience index include:

See also

External links

References

  1. Sardegna, Jill; Shelly, Susan; Rutzen, Allan Richard; Scott M Steidl (2002). The Encyclopedia of Blindness and Vision Impairment. Infobase Publishing. p. 253. ISBN 978-0-8160-6623-0. Retrieved 30 November 2014.
  2. Papoutsis, Ioannis; Nikolaou, Panagiota; Stefanidou, Maria; Spiliopoulou, Chara; Athanaselis, Sotiris (2014). "25B-NBOMe and its precursor 2C-B: modern trends and hidden dangers". Forensic Toxicology. 33 (1): 1–11. doi:10.1007/s11419-014-0242-9. ISSN 1860-8965. 
  3. Bersani, Francesco Saverio; Corazza, Ornella; Albano, Gabriella; Valeriani, Giuseppe; Santacroce, Rita; Bolzan Mariotti Posocco, Flaminia; Cinosi, Eduardo; Simonato, Pierluigi; Martinotti, Giovanni; Bersani, Giuseppe; Schifano, Fabrizio (2014). "25C-NBOMe: Preliminary Data on Pharmacology, Psychoactive Effects, and Toxicity of a New Potent and Dangerous Hallucinogenic Drug". BioMed Research International. 2014: 1–6. doi:10.1155/2014/734749. ISSN 2314-6133. 
  4. "Preliminary evidence of an association between sensorimotor gating and distractibility in psychosis". The Journal of Neuropsychiatry and Clinical Neurosciences. 8 (1): 60–66. 1996. doi:10.1176/jnp.8.1.60. ISSN 0895-0172. 
  5. McGhie, Andrew; Chapman, James (1961). "Disorders of attention and perception in early schizophrenia". British Journal of Medical Psychology. 34 (2): 103–116. doi:10.1111/j.2044-8341.1961.tb00936.x. ISSN 0007-1129. 
  6. Vollenweider, F. (2007). "Advances and Pathophysiological Models of Hallucinogenic Drug Actions in Humans: A Preamble to Schizophrenia Research". Pharmacopsychiatry. 31 (S 2): 92–103. doi:10.1055/s-2007-979353. ISSN 0176-3679. 
  7. Goddard, A. W.; Charney, D. S. Toward an integrated neurobiology of panic disorder. J. Clin. Psychiatry 58(suppl. 2):4–11; 1997. https://www.ncbi.nlm.nih.gov/pubmed/9078988
  8. Steriade, M.; Descheˆnes, M. Cellular thalamic mechanisms. In: Bentivoglio, M.; Spreafico, R., eds. Intrathalamic and brainstem-thalamic networks involved in resting and alert state. Amsterdam: Elsevier; 1988:37–62. https://ci.nii.ac.jp/naid/10017402609/en/
  9. Steriade, M; McCormick, D.; Sejnowski, T. (1993). "Thalamocortical oscillations in the sleeping and aroused brain". Science. 262 (5134): 679–685. doi:10.1126/science.8235588. ISSN 0036-8075. 
  10. 10.0 10.1 Vollenweider, Franz X; Geyer, Mark A (2001). "A systems model of altered consciousness: integrating natural and drug-induced psychoses". Brain Research Bulletin. 56 (5): 495–507. doi:10.1016/S0361-9230(01)00646-3. ISSN 0361-9230. 
  11. Vollenweider F. (1998). Recent advances and concepts in the search for biological correlates of hallucinogen-induced altered states of consciousness. Heffter Rev. Psychedel. Res. 1, 21–32. https://ci.nii.ac.jp/naid/10019112167/